Sanofi (SNY)’s MenQuadfi Becomes First MenACWY Vaccine Approved for Ages 6 Weeks and Up

The U.S. FDA has approved an expanded indication for Sanofi (NASDAQ:SNY)’s quadrivalent meningococcal vaccine, MenQuadfi, now allowing its use in children as young as 6 weeks old. Previously approved for individuals aged 2 years and older, MenQuadfi by Sanofi (NASDAQ:SNY) becomes the only MenACWY vaccine available for people from 6 weeks of age with no upper age limit.

The vaccine protects against invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroups A, C, W, and Y, a critical step, as infants are at the highest risk for IMD, which can be rapidly fatal.

A closeup of a vial of the biotechnology company’s vaccines.

The new dosing schedule includes a 4-dose series for infants starting at 2, 4, 6, and 12–18 months, and a 2-dose series for those 6–23 months, with a single dose for those 2 years and older. Clinical trials involving over 6,000 participants demonstrated MenQuadfi’s safety and strong immune response, comparable to other licensed vaccines.

Sanofi (NASDAQ:SNY)’s vaccine is supplied as a ready-to-use liquid in single-dose vials, streamlining administration. This expansion comes amid a recent rise in U.S. meningococcal disease cases, particularly serogroup Y, which MenQuadfi covers. The CDC’s Advisory Committee is expected to discuss implementation recommendations next month.

While we acknowledge the potential of SNY to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk.  If you are looking for an AI stock that is more promising than SNY and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Cancer Stocks to Invest in for Long-Term Gains and 10 Most Oversold Stocks to Buy According to Billionaires.

Disclosure: None.